

Inventor Search

10/694,448

Cook 10/694,432

01/10/2004

=> d ibib abs ind hitstr 17 1-2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:537491 HCAPLUS

DOCUMENT NUMBER: 135:117260

TITLE: Therapeutic use of D-methionine to reduce the toxicity of ototoxic drugs, noise, and radiation

INVENTOR(S): Campbell, Kathleen C. M.

PATENT ASSIGNEE(S): Southern Illinois University School of Medicine, USA

SOURCE: U.S., 23 pp., Cont.-in-part of U.S. 6,187,817.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6265386	B1	20010724	US 1998-57065	19980408
US 6187817	B1	20010213	US 1997-942845	19971002
PT 1019036	T	20031128	PT 1998-915362	19980408
ES 2202834	T3	20040401	ES 1998-915362	19980408
US 2002019443	A1	20020214	US 2001-911195	20010723
US 2004110719	A1	20040610	US 2003-694448	20031027
US 2004127568	A1	20040701	US 2003-694432	20031027
PRIORITY APPLN. INFO.:			US 1997-942845	A2 19971002
			US 1996-27750P	P 19961003
			US 1998-57065	A2 19980408
			US 2001-911195	A1 20010723

AB Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amts. of platinum-containing chemotherapeutic agents such as cisplatin are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.

IC ICM A61K031-70

ICS A61K031-195

NCL 514036000

CC 1-12 (Pharmacology)

Section cross-reference(s): 8

ST methionine cytoprotective ototoxicity drug radiation noise

IT Antibiotics

(aminoglycoside; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Diuretics

(loop; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT Body weight

- Hearing
(loss; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Cytoprotective agents
(neuroprotectants; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Toxicity
(neurotoxicity; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Chelating agents
(pharmaceutical; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Antitumor agents
(platinum-containing; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Acoustic noise
Alopecia
Cytoprotective agents
Ear
Radiation
(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT Digestive tract
Nerve
(toxicity; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT 7439-89-6, Iron, biological studies
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chelating agents; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT 56-54-2, Quinidine 57-92-1, Streptomycin, biological studies 59-01-8, Kanamycin 114-07-8, Erythromycin 130-95-0, Quinine 1403-66-3, Gentamicin 1404-04-2, Neomycin 1404-90-6, Vancomycin 6379-56-2, Hygromycin 7542-37-2, Paromomycin 14096-51-6, Dichloro(ethylenediamine)platinum(II) 14215-58-8, Chloro(diethylenetriamine)platinum(II) chloride 14913-33-8, trans-Diamminedichloroplatinum(II) 15663-27-1, Cisplatin 20115-64-4 32986-56-4, Tobramycin 37517-28-5, Amikacin 41575-93-3 41575-94-4, Carboplatin 41666-77-7 56391-56-1, Netilmicin 62928-11-4, Iproplatin 64363-09-3 67254-31-3 74790-08-2, Spiroplatin 114579-59-8 141610-50-6 148977-78-0 149055-58-3
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)
- IT 59-51-8, Methionine 63-68-3, L-Methionine, biological studies 348-67-4, D-Methionine 502-83-0, Methioninol

1319-79-5 6094-76-4, Homomethionine 13073-35-3

, Ethionine 29908-03-0, S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

IT 7439-89-6, Iron, biological studies

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chelating agents; therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 7439-89-6 HCAPLUS

CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT 56-54-2, Quinidine 57-92-1, Streptomycin, biological

studies 59-01-8, Kanamycin 114-07-8, Erythromycin

130-95-0, Quinine 1403-66-3, Gentamicin

1404-04-2, Neomycin 1404-90-6, Vancomycin

6379-56-2, Hygromycin 7542-37-2, Paromomycin

14096-51-6, Dichloro(ethylenediamine)platinum(II)

14215-58-8, Chloro(diethylenetriamine)platinum(II) chloride

14913-33-8, trans-Diamminedichloroplatinum(II) 15663-27-1

, Cisplatin 20115-64-4 32986-56-4, Tobramycin

37517-28-5, Amikacin 41575-93-3 41575-94-4,

Carboplatin 41666-77-7 56391-56-1, Netilmicin

62928-11-4, Iproplatin 64363-09-3 67254-31-3

74790-08-2, Spiroplatin 114579-59-8 141610-50-6

148977-78-0 149055-58-3


RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 56-54-2 HCAPLUS

CN Cinchonan-9-ol, 6'-methoxy-, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 57-92-1 HCAPLUS

CN D-Streptamine, O-2-deoxy-2-(methylamino)-α-L-glucopyranosyl-

(1→2)-O-5-deoxy-3-C-formyl- α -L-lyxofuranosyl-(1→4)-
N,N'-bis(aminoiminomethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 59-01-8 HCAPLUS

CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1→6)-O-
[6-amino-6-deoxy- α -D-glucopyranosyl-(1→4)]-2-deoxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 114-07-8 HCAPLUS

CN Erythromycin (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 130-95-0 HCAPLUS

CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 1403-66-3 HCAPLUS

CN Gentamicin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-04-2 HCAPLUS

CN Neomycin (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1404-90-6 HCAPLUS

CN Vancomycin (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

— Bu-i


PAGE 2-A



RN 6379-56-2 HCAPLUS

CN D-neo-Inositol, 5-deoxy-5-[[[(2E)-3-[4-[(6-deoxy-β-D-arabino-hexofuranos-5-ulos-1-yl)oxy]-3-hydroxyphenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylene- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 7542-37-2 HCAPLUS


CN D-Streptamine, O-2-amino-2-deoxy-α-D-glucopyranosyl-(1→4)-O-[O-2,6-diamino-2,6-dideoxy-β-L-idopyranosyl-(1→3)-β-D-ribofuranosyl-(1→5)]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 14096-51-6 HCAPLUS

CN Platinum, dichloro(1,2-ethanediamine-κN,κN')-, (SP-4-2)- (9CI)
(CA INDEX NAME)



RN 14215-58-8 HCAPLUS


CN Platinum(1+), [N-[2-(amino-κN)ethyl]-1,2-ethanediamine-κN,κN']chloro-, chloride, (SP-4-2)- (9CI) (CA INDEX NAME)




● Cl⁻

RN 14913-33-8 HCAPLUS


CN Platinum, diamminedichloro-, (SP-4-1)- (9CI) (CA INDEX NAME)



RN 15663-27-1 HCAPLUS
 CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 20115-64-4 HCAPLUS
 CN Platinum(2+), diamminediaqua-, (SP-4-2)- (9CI) (CA INDEX NAME)




RN 32986-56-4 HCAPLUS
 CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1 \rightarrow 6)-O-[2,6-diamino-2,3,6-trideoxy- α -D-ribo-hexopyranosyl-(1 \rightarrow 4)]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 37517-28-5 HCAPLUS
 CN D-Streptamine, O-3-amino-3-deoxy- α -D-glucopyranosyl-(1 \rightarrow 6)-O-[6-amino-6-deoxy- α -D-glucopyranosyl-(1 \rightarrow 4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 41575-93-3 HCAPLUS
 CN Platinum, diammine[ethylpropanedioato(2-)-κO1,κO3]-, (SP-4-2)-
 (9CI) (CA INDEX NAME)



RN 41575-94-4 HCAPLUS
 CN Platinum, diammine[1,1-cyclobutanedi(carboxylato-κO)(2-)]-,
 (SP-4-2)- (9CI) (CA INDEX NAME)




RN 41666-77-7 HCAPLUS
 CN Platinum, (1,2-ethanediamine-κN,κN')[propanedioato(2-)-
 κO1,κO3]-, (SP-4-2)- (9CI) (CA INDEX NAME)



RN 56391-56-1 HCAPLUS


CN D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)- β -L-arabinopyranosyl-(1 \rightarrow 6)-O-[2,6-diamino-2,3,4,6-tetradeoxy- α -D-glycero-hex-4-enopyranosyl-(1 \rightarrow 4)]-2-deoxy-N1-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62928-11-4 HCAPLUS

CN Platinum, dichlorodihydroxybis(2-propanamine)-, (OC-6-33)- (9CI) (CA INDEX NAME)




RN 64363-09-3 HCAPLUS


CN Platinum, aqua(1,2-cyclohexanediamine- κ N, κ N') [sulfato(2-)- κ O]-, (SP-4-3)- (9CI) (CA INDEX NAME)




RN 67254-31-3 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N')bis(2-oxopropanoato- κ O)-, (SP-4-2) - (9CI) (CA INDEX NAME)




RN 74790-08-2 HCAPLUS
 CN Platinum, (1,1-cyclohexanedimethanamine- κ N, κ N') [sulfato(2-)- κ O, κ O']-, (SP-4-2) - (9CI) (CA INDEX NAME)




RN 114579-59-8 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N') [propanedioato(2-)- κ O1, κ O3]-, (SP-4-2) - (9CI) (CA INDEX NAME)



RN 141610-50-6 HCAPLUS
 CN Platinum, (1,2-cyclohexanediamine- κ N, κ N') [ethanedioato(2-)- κ O1, κ O2]-, (SP-4-2) - (9CI) (CA INDEX NAME)




RN 148977-78-0 HCAPLUS
 CN Platinate(1-), (1,2-cyclohexanediamine- κ N, κ N') [1-hydroxy-1,2,3-propanetricarboxylato(3-)- κ O1, κ O2]-, hydrogen, (SP-4-3)- (9CI)
 (CA INDEX NAME)



● H⁺

RN 149055-58-3 HCAPLUS
 CN Platinate(1-), [1,2,4-benzenetricarboxylato(3-)- κ O1, κ O2] (1,2-cyclohexanediamine- κ N, κ N')-, hydrogen, (SP-4-3)- (9CI) (CA INDEX NAME)



● H⁺

IT 59-51-8, Methionine 63-68-3, L-Methionine, biological studies 348-67-4, D-Methionine 502-83-0, Methioninol

1319-79-5 6094-76-4, Homomethionine 13073-35-3


, Ethionine 29908-03-0, S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic use of D-methionine and related compds. to reduce toxicity of ototoxic drugs, noise, platinum-containing antitumor drugs, and radiation)

RN 59-51-8 HCAPLUS


CN Methionine (9CI) (CA INDEX NAME)



RN 63-68-3 HCAPLUS

CN L-Methionine (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348-67-4 HCAPLUS


CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 502-83-0 HCAPLUS

CN 1-Butanol, 2-amino-4-(methylthio)- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1319-79-5 HCAPLUS

CN L-Methionine, hydroxy- (9CI) (CA INDEX NAME)




D1-OH

RN 6094-76-4 HCAPLUS
 CN Norvaline, 5-(methylthio)- (9CI) (CA INDEX NAME)




RN 13073-35-3 HCAPLUS
 CN L-Homocysteine, S-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 29908-03-0 HCAPLUS
 CN Adenosine, 5'-[[[(3S)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-,
 inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:249071 HCAPLUS
 DOCUMENT NUMBER: 130:262147
 TITLE: Use of D-methionine or other methionine compound to reduce the toxicity of ototoxic drugs, noise, and radiation
 INVENTOR(S): Campbell, Kathleen C. M.
 PATENT ASSIGNEE(S): Southern Illinois University, USA
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
WO 9917765          A1      19990415      WO 1998-US6960      19980408
W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
    DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
    KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
    NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
    UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
    FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
    CM, GA, GN, ML, MR, NE, SN, TD, TG
US 6187817          B1      20010213      US 1997-942845      19971002
CA 2303901          AA      19990415      CA 1998-2303901     19980408
AU 9869568          A1      19990427      AU 1998-69568       19980408
AU 753039           B2      20021003
EP 1019036          A1      20000719      EP 1998-915362      19980408
EP 1019036          B1      20030625
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, FI
JP 2001518499       T2      20011016      JP 2000-514636      19980408
AT 243511           E       20030715      AT 1998-915362      19980408
PT 1019036          T       20031128      PT 1998-915362      19980408
ES 2202834          T3      20040401      ES 1998-915362      19980408
PRIORITY APPLN. INFO.:
                                US 1997-942845      A 19971002
                                US 1996-27750P      P 19961003
                                WO 1998-US6960      W 19980408

```

OTHER SOURCE(S): MARPAT 130:262147

AB Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amts. of platinum-containing chemotherapeutic agents, e.g. cisplatin, are provided. Methods are also provided for preventing or reducing such symptoms in patients undergoing treatment with loop diuretics, aminoglycoside antibiotics, iron chelating agents, quinine, and quinidine, or those who have been exposed to toxic levels of noise or radiation. These methods comprise administering an effective amount of a methionine protective agent, e.g. D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent, loop diuretic agent, etc., or exposure to noise or radiation. Combinations of these time periods can also be employed.

IC ICM A61K031-195

ICS A61K031-10

CC 1-12 (Pharmacology)

Section cross-reference(s): 63

ST methionine protection **ototoxic** drug noise **radiation**

IT Antibiotics

(aminoglycoside; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Digestive tract

(disease; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Toxicity

(drug; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Drugs

(gastrointestinal; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Chelating agents

(iron; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Diuretics

(loop; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Alopecia
Drug delivery systems
Ear
Noise
Radiation
Radioprotectants
(methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Toxicity
(neurotoxicity; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT Nerve
(toxicity; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 7439-89-6, Iron, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chelating agents; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 56-54-2, Quinidine 130-95-0, Quinine 15663-27-1
, Cisplatin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)

IT 59-51-8, Methionine 59-51-8D, Methionine, compds.
59-51-8D, Methionine, derivs. 63-68-3, L-Methionine,
biological studies 63-68-3D, L-Methionine, derivs., biological
studies 348-67-4, D-Methionine 348-67-4D,
D-Methionine, derivs. 502-83-0, Methioninol 1319-79-5
13073-35-3, Ethionine 29908-03-0, S-Adenosyl-L-
methionine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(methionine compds. to reduce toxicity of **ototoxic** drugs,
noise, and **radiation**)

IT 7439-89-6, Iron, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(chelating agents; methionine compds. to reduce toxicity of **ototoxic** drugs, noise, and **radiation**)


RN 7439-89-6 HCAPLUS
CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT 56-54-2, Quinidine 130-95-0, Quinine 15663-27-1
, Cisplatin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(methionine compds. to reduce toxicity of **ototoxic** drugs,
noise, and **radiation**)

RN 56-54-2 HCAPLUS
CN Cinchonan-9-ol, 6'-methoxy-, (9S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 130-95-0 HCAPLUS


CN Cinchonan-9-ol, 6'-methoxy-, (8α,9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15663-27-1 HCAPLUS

CN Platinum, diamminedichloro-, (SP-4-2)- (9CI) (CA INDEX NAME)




IT 59-51-8, Methionine 59-51-8D, Methionine, compds.
 63-68-3, L-Methionine, biological studies 63-68-3D,
 L-Methionine, derivs., biological studies 348-67-4, D-Methionine
 348-67-4D, D-Methionine, derivs. 502-83-0, Methioninol
 1319-79-5 13073-35-3, Ethionine 29908-03-0,
 S-Adenosyl-L-methionine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(methionine compds. to reduce toxicity of ototoxic drugs, noise, and radiation)

RN 59-51-8 HCAPLUS

CN Methionine (9CI) (CA INDEX NAME)




RN 59-51-8 HCAPLUS
CN Methionine (9CI) (CA INDEX NAME)




RN 63-68-3 HCAPLUS
CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 63-68-3 HCAPLUS
CN L-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348-67-4 HCAPLUS
CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 348-67-4 HCAPLUS
CN D-Methionine (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 502-83-0 HCAPLUS

CN 1-Butanol, 2-amino-4-(methylthio)- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1319-79-5 HCAPLUS

CN L-Methionine, hydroxy- (9CI) (CA INDEX NAME)




D1-OH

RN 13073-35-3 HCAPLUS

CN L-Homocysteine, S-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 29908-03-0 HCAPLUS

CN Adenosine, 5'-[[(3S)-3-amino-3-carboxypropyl]methylsulfonio]-5'-deoxy-, inner salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.86

41.89

Cook 10/694,432

01/10/2004

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.40	-3.50

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:17:31 ON 01 OCT 2004